SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM). There is a clear medical need for new, safe and effective treatments with the potential to improve care for the estimated 10 million FM patients in the Read More

Results from a Pivotal Phase 3, DB, R, Placebo-controlled, Multicenter Trial of SP-102, a Novel Dexamethasone Injectable Formulation, for the Treatment of Patients with Lumbosacral Radiculopathy (Sciatica)  SP-102 (SEMDEXA TM ) is the first non-opioid novel injectable corticosteroid gel formulation Read More

SAN DIEGO, CA AND PALO ALTO, CA. April 28, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), who is a commercial biopharmaceutical company focused on developing and commercializing Read More

PALO ALTO, CA. April 27, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for Read More

San Diego, CA and Palo Alto, CA., April 25, 2022 (GLOBE NEWSWIRE)  – Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive Chairman of Scilex Holding Company (“Scilex”), will participate in the B. Read More

PALO ALTO, CA. April 25, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for Read More

PALO ALTO, CA. April 12, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for Read More

ZTlido 53% year-over-year preliminary unaudited gross sales in March 2022 Select payor accounts representing approximately 200 million of the over 300 million covered lives across the United States PALO ALTO, CA. April 4, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), a nearly 100% (or over Read More

PALO ALTO, CA. March 25, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and Read More

SP-102 (SEMDEXA™), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy) experienced a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affected leg, with highly statistically significant Read More